In a recent development, €4 million in additional financing has been secured by CroíValve, a high potential startup (HPSU) supported by Enterprise Ireland, developing a treatment for tricuspid regurgitation (TR).
This is an issue affecting over half-a-million people every year in the US and EU alone, for which there is currently no suitable solution. The financing includes €2.5 million from the European Union under their Horizon 2020 SME Instrument grant and €1.5 million from Broadview Ventures and current investors (HBAN MedTech and Irrus Syndicates, Atlantic Bridge University Fund and SOS Ventures).